Cardiff Oncology Inc (NASDAQ: CRDF) stock closed at $3.08 on 11/8/24 after a major decline of -24.7%. Moreover, this decline was accompanied by exceptionally high trading volume at 491% of normal. The stock has declined -1.3% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, CRDF is expected to continue to be Value Creation neutral.
Cardiff Oncology has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Cardiff Oncology has a very low Power Rating of 9 and a very low Appreciation Score of 8, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment